🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Vehicle cream: same formulation of cream as the test product but without active substance and phosphoric acid, Ruxolitinib (INCB018424) cream

    Incyte

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial
  2. Veltassa 8.4 g powder for oral suspension, Placebo

    Istituto Gentili S.r.l.

    End Stage Kidney Disease on chronic dialysis therapy

    phase 3 small molecule active

    1 trial
  3. Venclexta, Venclyxto, Levact 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Venclexta, Venclyxto, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Venclexta, Venclyxto, Fludarabin Ebewe 25 mg/ml injektio-/infuusiokonsentraatti, liuosta varten, Fludarabin Sandoz 25 mg/ml injekčný alebo infúzny koncentrát, MabThera 500 mg concentrate for solution for infusion, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, Bendamustin cell pharm® 2,5

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial
  4. Venetoclax

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML

    phase 3 small molecule active

    2 trials
  5. Venetoclax

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  6. Venetoclax

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial
  7. Venetoclax in combination with fludarabine and melphalan

    The First People's Hospital of Lianyungang

    Venentoclax

    phase 3 small molecule active

    1 trial
  8. Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use

    AbbVie Deutschland GmbH & Co. KG

    Higher-Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial
  9. Ventoclax

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 3 small molecule active

    1 trial
  10. Ventolin 100 microgramos/inhalación suspensión para inhalación en envase a presión* (*) sin CFC

    GlaxoSmithKline

    Asthma

    phase 3 small molecule active

    1 trial
  11. Venues-P Valve

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pulmonary Regurgitation

    phase 3 other active

    1 trial
  12. Verum acupuncture

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer

    phase 3 other active

    1 trial
  13. Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet

    The George Institute

    Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodysplastic Symdrome (MDS), Myelodysplastic Symdrome (MDS)

    phase 3 small molecule active

    1 trial
  14. Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet, Placebo to Match AG-120 Tablet, 250 mg, is supplied as a film-coated tablet for oral administration.

    The George Institute

    Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

    phase 3 small molecule active

    1 trial
  15. Vidaza 25 mg/ml powder for suspension for injection, Gilteritinib

    Astellas Pharma GmbH

    Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

    phase 3 small molecule active

    1 trial
  16. Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets

    The George Institute

    Acute Myeloid Leukemia, ONCOLOGY

    phase 3 small molecule active

    1 trial
  17. Vincristine Sulfate Liposome

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adult Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial
  18. Visilizumab

    The First People's Hospital of Lianyungang

    Immunotherapy

    phase 3 small molecule active

    1 trial
  19. Vitamin D3

    Hospital Authority, Hong Kong

    Lupus Erythematosus, Systemic

    phase 3 small molecule completed

    1 trial
  20. Vocabria 600 mg prolonged-release suspension for injection, REKAMBYS 900 mg prolonged-release suspension for injection

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 3 small molecule active

    1 trial
  21. Voclosporin

    Aurinia Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule completed

    3 trials
  22. Voclosporin

    Aurinia Pharmaceuticals

    Adolescent Lupus Nephritis

    phase 3 small molecule terminated

    2 trials
  23. Vyloy 100 mg powder for concentrate for solution for infusion., OXALIPLATIN, FOLINIC ACID, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, FLUOROURACIL, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Vyloy 100 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sodium chloride 0.9% intravenous infusion, ASP8951, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate fo

    Astellas Pharma GmbH

    Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial
  24. Warfarin Sodium

    Hospital Authority, Hong Kong

    Indications for Warfarin Therapy

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources